Altimmune Inc

NASDAQ:ALT   3:59:50 PM EDT
11.40
-0.12 (-1.04%)
Products, Regulatory, Earnings Announcements

Altimmune Announces Positive Results From 12-Week Phase 1 Clinical Trial Of ALT-801 In Overweight And Obese Volunteers

Published: 09/28/2021 11:14 GMT
Altimmune Inc (ALT) - Altimmune Announces Positive Results From 12-week Phase 1 Clinical Trial of Alt-801 (pemvidutide) in Overweight and Obese Volunteers.
Altimmune Inc - Pemvidutide Was Well-tolerated Without Need for Dose Titration.
Altimmune Inc - Nash Ind Has Cleared FDA Review; 12-week Nafld Study to Begin in Near Future.
Altimmune Inc - No Discontinuations Due to Treatment-emergent Adverse Events.
Altimmune Inc - Mean Weight Loss of 10.3% Achieved in Subjects Receiving 1.8 Mg Dose.
Altimmune Inc - Intends to File a Second Ind Application in Obesity in Q4 2021 With Plans to Initiate a 48-week, Phase 2 Obesity Trial in H1 2022.
Altimmune Inc - Intends to Begin a 52-week Phase 2 Biopsy-driven Nash Trial in H1 2022.
Revenue is expected to be $0.07 Million
Adjusted EPS is expected to be -$0.39

Next Quarter Revenue Guidance is expected to be $0.07 Million
Next Quarter EPS Guidance is expected to be -$0.43

More details on our Analysts Page.